References
- Adachi H, Nakayama K, Ozaki M, Uwagawa S, Seki T, Matsuo M. Five-day intravenous comparative toxicity study on amrubicin hydrochloride (SM-5887) and doxorubicin hydrochloride (DXR) in male rats. Japanese Pharmacology and Therapy 1999; 27S: 221–239
- Bartoszek A. Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects. Acta Biochemica Polonica 2002; 49: 323–331
- Chapman DE, Michener SR, Powis G. Metabolism of 2,6-dinitro[3-3H]toluene by human and rat liver microsomal and cytosolic fractions. Xenobiotica 1992; 22: 1015–1028
- Cummings J, Allan L, Willmott N, Riley R, Workman P, Smyth JF. The enzymology of doxorubicin quinone reduction in tumour tissue. Biochemistry and Pharmacology 1992; 44: 2175–2183
- Di MD, Shinka T, Sandy MS, Castagnoli N, Jr, Smith MT. Quantitative analysis of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism in isolated rat hepatocytes. Drug Metabolism and Disposition 1988; 16: 250–255
- Forrest GL, Gonzalez B, Tseng W, Li X, Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Research 2000; 60: 5158–5164
- Kuffel MJ, Ames MM. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells. Cancer Chemotherapy and Pharmacology 1995; 36: 223–226
- Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, Meucci E. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: Biochemical aspects and pharmacologic implications. Biochemistry and Pharmacology 2003; 66: 989–998
- Mross K, Maessen P, Van der Vijgh WJ, Gall H, Boven E, Pinedo HM. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. Journal of Clinical Oncology 1988; 6: 517–526
- Nakai S, Akao K, Ito M, Kanamaru H, Nakatsuka I. Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (IV): Metabolism of SM-5887 in rats and dogs. Xenobiotic Metabolism and Disposition 1998; 13: 100–112
- Nakai S, Akao K, Ito M, Kanamaru H, Nakatsuka I. Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (6) — pharmacokinetic studies of amrubicinol, the major bioactive metabolite of amrubicin, in rats. Japanese Pharmacology and Therapy 1999; 27S: 521–543
- Nakai S, Ito M, Kanamaru H, Nakatsuka I. Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (9) — in vitro chiral conversion of SM-5887 and stereoselectivity of reduction of the carbonyl group at the C-13 position. Japanese Pharmacology and Therapy 1999; 27S: 557–568
- Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Japanese Journal of Cancer Research 1998; 89: 1061–1066
- Schott B, Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochemistry and Pharmacology 1989; 38: 4069–4074
- Siddik ZH, Jones M, Boxall FE, Harrap KR. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemotherapy and Pharmacology 1988; 21: 19–24
- Takanashi S, Bachur NR. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metabolism and Disposition 1976; 4: 79–87
- Tanaka K, Inoue T, Kadota S, Kikuchi T. Metabolism by rat liver cytosol of illudin S, a toxic substance of Lampteromyces japonicus. II. Characterization of illudin S-metabolizing enzyme. Xenobiotica 1992; 22: 33–39
- Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Japanese Journal of Cancer Research 1998; 89: 1067–1073